Comparative Pharmacology
Head-to-head clinical analysis: CLADRIBINE versus HALAVEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLADRIBINE versus HALAVEN.
CLADRIBINE vs HALAVEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateCladribine + Digoxin
"Cladribine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCladribine + Digitoxin
"Cladribine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCladribine + Deslanoside
"Cladribine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCladribine + Acetyldigitoxin
"Cladribine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent